drugset / Trial / NCT01100021

Hemodynamic Study of Avanafil and Two α-Adrenergic Blockers,Doxazosin and Tamsulosin

NCT01100021 ↗

Phase 1 Completed 48 enrolled VIVUS LLC
RandomizedCrossoverQuadruple-blindTreatment

Summary

The purpose of this study is to see if avanafil causes any changes in blood pressure and pulse rate when taken with doxazosin or tamsulosin.

Timeline

Start
2010-02
Primary completion
2010-03
Completion
2010-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Avanafil Small molecule 200 mg —
Subject Doxazosin Unknown 8 mg —
Subject Tamsulosin Other / unclassified 0.4 mg —

Indications